NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Clinical Trials
11 trialsNCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT06643962 2024-11-12
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University
Phase NA Recruiting
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT00780104 2019-07-12
UPCC 02407
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00065143 2018-11-07
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01880437 2015-12-15
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
Hoffmann-La Roche
Phase 2 Terminated
NCT01321346 2015-11-24
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00451997 2012-08-01
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00129168 2008-04-01
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Kanisa Pharmaceuticals
Phase 1/2 Completed